STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Enveda, a Boulder, Colorado biotech founded in 2019, announced Phase 1 results Tuesday in a press release for an oral drug candidate that imitates lac-phe — a small-molecule metabolite discovered by Stanford scientists.
- The pill aims to limit appetite and re-create exercise's preservation of lean muscle mass, which the company hopes will allow weight-loss maintenance without the gastrointestinal side effects common to GLP-1 drugs.
- The muscle-preservation focus targets a specific GLP-1 concern: patients who yo-yo on and off the medications lose more muscle with each cycle.
- Lac-phe (lactate phenylalanine), discovered by Stanford scientists, is the metabolite Enveda's oral pill is designed to mimic, positioning it as an alternative to injectable GLP-1 therapies.
Why it matters: Enveda's pill enters the obesity-drug field at Phase 1 — years from any patient reach — but its dual claim of appetite suppression plus muscle preservation directly targets documented GLP-1 limitations. Investors and pharma partners will watch whether early signals hold, though the press release disclosed no trial timeline or licensing plans.
Ask SkimNews
